Search
Crotalus scutulatus antivenin
go.drugbank.com/drugs/DB13891ApprovedSince it was approved by the Food and Drug Administration in October 2000, crotalidae poyvalent immune Fab (CroFab) has largely replaced previously used crotaline antivenom. … The final purified antivenin product is obtained by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques.
Antihemophilic factor, human recombinant
go.drugbank.com/drugs/DB00025ApprovedInvestigationalHuman recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
Glutethimide
go.drugbank.com/drugs/DB01437ApprovedIllicitIts use has been largely superseded by other drugs.
Propyl alcohol
go.drugbank.com/drugs/DB03175ApprovedA colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.
Hydrocortamate
go.drugbank.com/drugs/DB00769ApprovedGlucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic
Cannabidivarin
go.drugbank.com/drugs/DB14050InvestigationalCompared to its homolog, [DB09061], CBDV is shortened by two methyl (CH2) groups on its side chain. … In October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome [L2952] and again in February 2018 for treatment of Fragile X Syndrome [L2951].
Magnesium citrate
go.drugbank.com/drugs/DB11110ApprovedInvestigational[T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg.
Lactic acid
go.drugbank.com/drugs/DB04398ApprovedInvestigationalVet approvedIt is produced by fermentation of a sugar source, such as corn or beets, and then, by neutralizing the resulting lactic acid to create a compound having the formula NaC3H5O3. … Lactic acid was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor
Imidafenacin
go.drugbank.com/drugs/DB09262InvestigationalIt is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.